Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus VemurafenibMatthew J Wongchenko, Grant A McArthur, Brigitte Dréno, et al.
Scientific Reports|March 17, 2023
Predicting EGFR mutational status from pathology images using a real-world datasetJames J Pao, Mikayla Biggs, Daniel Duncan, et al.
The Oncologist|May 22, 2022
Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung CancerKarthikeyan Murugesan, Dexter X Jin, Leah A Comment, et al.
Cancer Discovery|April 16, 2023
Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic TransformationSmruthy Sivakumar, Jay A Moore, Meagan Montesion, et al.
Immunity|October 11, 2023
The cancer-immunity cycle: Indication, genotype, and immunotypeIra Mellman, Daniel S Chen, Thomas Powles, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
The Journal of Clinical Investigation|August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacyLeisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|January 19, 2018
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for AtezolizumabBharathi Vennapusa, Brian Baker, Marcin Kowanetz, et al.
Nature Communications|December 5, 2022
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancerSmruthy Sivakumar, Dexter X Jin, Hanna Tukachinsky, et al.
JCO Precision Oncology|September 28, 2023
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor ResponseJay A Moore, Kuei-Ting Chen, Russell Madison, et al.
Pageof 8